MoonLake Immunotherapeutics
MLTX
24 hedge funds and large institutions have $291M invested in MoonLake Immunotherapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.
53% more capital invested
Capital invested by funds: $190M → $291M (+$101M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 23 → 24 (+1)
1.04% more ownership
Funds ownership: 98.75% → 99.8% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.37M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.12M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$706K |
| 4 |
JG
Jefferies Group
New York
|
+$478K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$424K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.64M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$424K |
| 3 |
Millennium Management
New York
|
-$147K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$118K |
| 5 |
CAC
Cowen and Company
New York
|
-$85K |
MLTX Hedge Fund Activity: Q3 2022 in Review
24 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2022, worth a combined $291M — up 53% from $190M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MLTX positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.37M. The largest seller was Fidelity Investments, cutting an estimated $2.64M.
- 24 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2022, up from 23 in Q2 2022.
- Funds reported $291M of MoonLake Immunotherapeutics stock for Q3 2022, up 53% quarter-over-quarter.
- 5 funds opened new MoonLake Immunotherapeutics positions in Q3 2022 and 4 closed out, a net change of +1 holder.
- The largest MoonLake Immunotherapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $2.37M added.
- The largest MoonLake Immunotherapeutics seller in Q3 2022 was Fidelity Investments, an estimated $2.64M sold.
Based on aggregated 13F filings for Q3 2022.